Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Successful Scale-Up in the Production of CodeXol® Detergent Alcohols

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Codexis and Chemtex achieve key milestone in commercial development of bio-based chemicals from non-food cellulosic biomass.

Codexis and Chemtex have announced the successful scale-up in the production of CodeXol® detergent alcohols using cellulosic sugars.

The scale-up was achieved at a 1,500 liter demonstration facility at Chemtex’s R&D complex in Tortona, Italy and is a key milestone in the ongoing effort initiated by the two companies to develop a fully integrated biomass to detergent alcohols technology.

A combination of Chemtex’s commercially proven PROESA®cellulosic sugar technology and Codexis’ CodeXyme® 4X cellulase enzymes was used to produce cellulosic sugars from non-food biomass, while the CodeXol® detergent alcohol fermentation process technology - which includes Codexis’ proprietary microorganism strain - converted these cellulosic sugars to detergent alcohols.

Guido Ghisolfi, President of Chemtex, said, “While the PROESA® technology is proven at commercial scale for the production of cellulosic ethanol - as evidenced by the successful start-up of our commercial facility in Crescentino, Italy - this achievement is further proof that our platform cellulosic sugar technology is best-in-class for producing a broad range of bio-based chemicals using sustainable, non-food sources of biomass. It also validates our conviction that scaling up these technologies beyond the lab is key to enabling the learning curve towards commercial viability.”

John Nicols, President and CEO of Codexis, said, “This scale-up of CodeXol® detergent alcohols represents what we believe is the world’s first successful large scale effort to produce commercially relevant detergent alcohols from a cellulosic biomass feedstock. We believe this scale-up demonstrates the robustness and efficacy of our CodeXyme®cellulase enzymes and the ability of our CodeXol® detergent alcohol technology to produce detergent alcohols at commercial specification with the potential to decrease manufacturing costs below incumbent production costs.”

Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents.

The annual global market for detergent alcohols, which are currently manufactured from natural oils and fats and petrochemicals, is approximately $4 billion and is expected to reach $5.5 billion by 2020.

Codexis and Chemtex initiated an effort in 2011 to produce these high-value chemicals from sustainable, low-cost and non-food sources of biomass, which has the potential to offer attractive production economics compared to incumbent production routes.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Codexis Announces CodeEvolver Technology License Agreement with Merck
Codexis to receive $5 million in upfront payment.
Friday, August 07, 2015
Codexis Sign Technology License Agreement with GSK
Codexis to receive up to $25M of initial payments, plus additional milestone and royalty opportunities.
Wednesday, July 16, 2014
Codexis Sells its Hungarian Operations
The Hungarian subsidiary is sold for $1.5 million to Intrexon Corporation.
Friday, March 14, 2014
Codexis Appoints Patrick Yang to Board of Directors
Dr. Yang brings significant experience in pharmaceutical manufacturing and process development.
Friday, February 28, 2014
Purolite and Codexis Announce Collaboration
Purolite Corporation and Codexis, Inc. announced a joint collaboration to develop and market immobilized enzymes for the pharmaceutical industry.
Thursday, July 18, 2013
Codexis Appoints Vice President of Sales and Marketing
Appointment of Scott Watson as Vice President.
Thursday, June 06, 2013
Codexis Selected for Third Presidential Green Chemistry Award in Seven Years
The award, from the U.S. Environmental Protection Agency, is for the development of an efficient biocatalytic process to manufacture simvastatin, a leading drug for treating high cholesterol.
Tuesday, June 19, 2012
USPTO Grants Codexis Patent for Enzymes Used in Hep-C Therapeutics
Highlights how Codexis platform enables breakthrough biocatalytic processes.
Friday, May 18, 2012
Nature Highlights Advancements in Biocatalysis
Highlights potential impact on the production of biofuels, renewable chemicals, and pharmaceuticals.
Friday, May 11, 2012
Codexis Awarded Biofuels Enzyme Patent
Patent is cornerstone for company’s cellulosic biofuels program.
Wednesday, March 28, 2012
Codexis Names Wes Bolsen VP and Chief Marketing Officer
Mr Bolsen will have responsibility for the company's corporate marketing and communications.
Tuesday, December 06, 2011
Veteran Chemical Executive to Lead Codexis do Brasil
Achilles Antonio Clement has been named Director, Latin America with responsibility for managing Codexis' expanding role in Latin America.
Thursday, October 13, 2011
Codexis Licenses new Drug Metabolite Profiling and Lead Diversification Technology from Caltech
Codexis will incorporate the licensed technology in development of new R&D productivity tools for use by the pharmaceutical industry.
Thursday, August 30, 2007
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!